6-(2-chloro-6-fluorophenyl)-2-[(2,4,4-trimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino]imidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one | 1395028-22-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 6-(2-chloro-6-fluorophenyl)-2-[(2,4,4-trimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino]imidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one
• 英文别名: Imidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one, 6-(2-chloro-6-fluorophenyl)-2-[(1,2,3,4-tetrahydro-2,4,4-trimethyl-7-isoquinolinyl)amino]-；7-(2-chloro-6-fluorophenyl)-12-[(2,4,4-trimethyl-1,3-dihydroisoquinolin-7-yl)amino]-2,5,7,11,13-pentazatricyclo[7.4.0.02,6]trideca-1(13),3,5,9,11-pentaen-8-one
• CAS: 1395028-22-4
• 化学式: C₂₆H₂₃ClFN₇O
• 分子量: 503.966
• InChiKey: LZNRTNXWTSKNMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  36
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  79.2
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• TRICYCLIC INHIBITORS OF KINASES
  申请人：Tong Yunsong

  公开号：US20120220572A1

  公开（公告）日：2012-08-30

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein X, Y, Z, R 3 and R 4 are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.

  本发明涉及式(I)的化合物或药用可接受的盐，其中X、Y、Z、R3和R4在描述中有定义。本发明还涉及含有上述化合物的组合物，用于抑制wee-1等激酶，并治疗癌症等疾病的方法。
• US8710065B2
  申请人：——

  公开号：US8710065B2

  公开（公告）日：2014-04-29
• [EN] TRICYCLIC INHIBITORS OF KINASES<br/>[FR] INHIBITEURS TRICYCLIQUES DE KINASES
  申请人：ABBOTT LAB

  公开号：WO2012161812A1

  公开（公告）日：2012-11-29

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, ( l ) wherein X, Y, Z, R3 and R4 are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.
• [EN] METHODS AND COMPOSITIONS FOR TREATING CANCER<br/>[FR] MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DU CANCER
  申请人：ENGINE BIOSCIENCES PTE LTD

  公开号：WO2021202780A2

  公开（公告）日：2021-10-07

  Methods and compositions for treating cancer are disclosed herein. The methods may comprise use of therapeutically effective amounts of one or more therapeutic agents to cause a difference in expression or activity of protein kinase, membrane associated tyrosine/threonine 1 (PKMYT1) in cancer cells that are deficient in protein phosphatase 2 regulatory subunit B alpha (PPP2R2A).